New combo therapy aims to ease lung pressure in scarred lungs

NCT ID NCT07333183

First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 29 times

Summary

This study tests whether adding a new inhaled drug, mosliciguat, to an existing treatment (treprostinil) is safe for people with high blood pressure in the lungs caused by lung scarring. About 20 adults with this condition will receive the combination and be monitored for side effects. The goal is to find a safer way to manage this serious lung disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC

    RECRUITING

    Kissimmee, Florida, 34746, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.